BioNTech – Talk Bio

Bristol Myers Squibb Commits Up to $11B+ in Major BioNTech Solid Tumor Bispecific Antibody Deal

5 days ago talkbio0Tagged Antibodies, Bispecific, BioNTech, BNT327, Immunotherapy for cancer, milestone payments, Myers, Partnership, PD-L1, Solid Neoplasm, squibb, Vascular Endothelial Growth Factor A

Bristol Myers Squibb; BioNTech; BNT327; bispecific antibody; solid tumors; PD-L1; VEGF-A; cancer immunotherapy; partnership; milestone payments

Bristol Myers Squibb Signs $11B Deal With BioNTech for Bispecific Cancer Antibody BNT327, Surpassing Recent Merck and Pfizer Moves

6 days ago talkbio0Tagged Antibodies, Bispecific, BioNTech, biotech partnerships, BNT327, immuno-oncology, Malignant Neoplasms, Myers, PD-L1, Solid Neoplasm, squibb, Vascular Endothelial Growth Factor A

Bristol Myers Squibb; BioNTech; BNT327; bispecific antibody; immuno-oncology; cancer; PD-L1; VEGF-A; solid tumors; biotech partnerships

DualityBio Pursues $200M IPO in Hong Kong Amid Volatile Market Conditions

2 months ago talkbio0Tagged Antibody-Drug, BioNTech, biotech sector, DualityBio, global trade tensions, Hong, Immunostimulating conjugate (antigen), Investments, IPO, Kong, Market, Stock exchange, upheaval

DualityBio, IPO, Hong Kong Stock Exchange, biotech investment, antibody-drug conjugates, BioNTech, market upheaval, global trade tensions, biotech sector growth.

BioNTech shows off lung cancer survival data behind phase 3 push for red-hot bispecific

2 months ago talkbio0Tagged BioNTech, BioNTech 's, BNT327, month, Pharmacotherapy, Small cell carcinoma of lung

BNT327, BioNTech, month, BioNTech ‘s, Small cell carcinoma of lung, Pharmacotherapy

FDA Pauses BioNTech’s Malaria Vaccine Trial Amid Regulatory Scrutiny

3 months ago talkbio0Tagged BioNTech, Malaria, regulatory, RNA Vaccine, Study on Hold, United States Food and Drug Administration, Vaccines

BioNTech, malaria vaccine, FDA clinical hold, RNA vaccine, regulatory challenges

BioNTech Resolves COVID-19 Vaccine Royalty Disputes with NIH and UPenn

5 months ago talkbio0Tagged Agreement, BioNTech, COVID19 (disease), Disputes, NIH Mouse, Pfizer, Royalty, settlement, UPenn, Vaccines

BioNTech, COVID-19 vaccine, royalty disputes, NIH, UPenn, Pfizer, settlement agreements

BioNTech Advances PD-L1/VEGF Bispecific Antibody with Encouraging Breast Cancer Trial Results

6 months ago talkbio0Tagged Antibodies, Bispecific, BioNTech, BNT327/PM8002, Clinical Trials, Combined Modality Therapy, Malignant neoplasm of breast, PD-L1/VEGF

BioNTech, PD-L1/VEGF Bispecific Antibody, BNT327/PM8002, Breast Cancer, Oncology Strategy, Clinical Trials, Combination Therapies

BioNTech Acquires Biotheus for $800M to Enhance Oncology Strategy with Promising Bispecific Antibody

7 months ago talkbio0Tagged Acquisition, Antibodies, Bispecific, BioNTech, Biotheus, BNT327/PM8002, Cancer Therapeutic Procedure, Neoplasms, PD-L1, Vascular Endothelial Growth Factor A

BioNTech, Biotheus, oncology, bispecific antibody, BNT327/PM8002, PD-L1, VEGF-A, cancer treatment, acquisition

BioNTech Invests $800M in PD-L1xVEGF-A Bispecific, Aiming to Challenge Keytruda Dominance

7 months ago talkbio0Tagged BioNTech, Biotheus, bispecific, Drug Industry, Immunotherapy for cancer, Keytruda, PD-L1xVEGF-A

BioNTech, Keytruda, PD-L1xVEGF-A bispecific, Biotheus, cancer immunotherapy, pharmaceutical industry

BioNTech Beats Q3 Expectations but Trims Full-Year Revenue Guidance Amid COVID-19 Vaccine Sales

7 months ago talkbio0Tagged BioNTech, COVID19 (disease), earnings, Immunotherapy, mRNA-based, Oncology Development, revenue guidance, Vaccines

BioNTech, Q3 earnings, COVID-19 vaccine, Revenue guidance, Oncology development, mRNA-based immunotherapies